ClinicalTrials.gg
RecruitingNCT07597512CLORINA-ICUpdated Sep 28, 2026

Urinary Chloride and Sodium Changes and Residual Congestion in Acute Heart Failure

An observational study in Acute Heart Failure (AHF), Heart Failure and Congestion, sponsored by Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal. Recruiting at 4 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · Observational

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Sep 28, 2026Now RecruitingSite recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
223
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 342 studies in Heart Failure with a site in Spain — 76 open to participants now, 99 under way, 21 of them phase 3. Heart Failure · Spain.

Planned enrollment
53rd of 78
223 · median 500
Started
2026
with 21 others
Observational
78 of 342
18 open now
Primary completion
2028-12
later than 79 of 98 live
Registered
335th of 342
by date

Among the 342 studies in Heart Failure with a site in Spain, this one is the 53rd largest by planned enrollment of the 78 observational ones that give a count, is one of 22 that started in 2026, is one of 78 observational ones, reaches primary completion later than 79 of the 98 other live ones, and was the 335th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

76 of the 342 studies in Heart Failure with a site in Spain are open now. Recruiting first, the newest first:

70 more — sign in →

All 76 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 342 studies in Heart Failure with a site in Spain, or all of them as a file.
02

Study summary

The goal of this observational study is to learn how changes in urinary sodium and chloride levels relate to fluid overload and short-term outcomes in patients hospitalized with acute heart failure (AHF). The main questions it aims to answer are:

  • Do changes over time in urinary sodium and chloride reflect how well excess fluid is being removed during hospitalization?
  • Are these changes associated with residual congestion at discharge and with the risk of worsening heart failure or death after discharge?

Participants hospitalized for AHF and treated with intravenous diuretics as part of their usual care will have clinical assessments, blood and urine tests, and echocardiographic evaluations collected at several time points during their hospital stay. Researchers will also record clinical outcomes, including worsening heart failure or death, at 30 days and 3 months after discharge.

Read the detailed description

This is a prospective, multicenter observational study. A minimum required sample size of n = 223 patients completing the study is planned. This study will include patients hospitalized for AHF and treated with intravenous diuretics. Clinical, biochemical, echocardiographic parameters, and circulating biomarkers (NT-proBNP, CA125, sST2, bioADM, and CD146) will be collected serially during hospitalization. Additionally, clinical events (worsening heart failure and/or all-cause mortality) will be recorded at 30 days and 3 months after discharge. Decongestion will be assessed using a multiparametric approach, incorporating clinical evaluation, echographic parameters, and estimated plasma volume status.

03

Conditions studied

  • Acute Heart Failure (AHF)
  • Heart Failure
  • Congestion

Browse trials for

Keywords

  • Acute Heart Failure
  • Heart failure
  • Biomarkers
  • Congestion
  • Urinary chloride
  • Urinary sodium
  • Diuretics
  • point of care ultrasound
  • POCUS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients of both sexes hospitalized for acute heart failure (AHF) in Internal Medicine and Cardiology departments at Spanish hospitals, presenting with signs of fluid overload and receiving intravenous (IV) diuretic therapy. The clinical diagnosis of heart failure will be established based on the presence of typical signs and symptoms, evidence of underlying structural heart disease on transthoracic echocardiography performed within the previous 24 months, and elevated natriuretic peptides measured at least 24 hours prior to inclusion. Patients across the full spectrum of left ventricular ejection fraction (LVEF) will be included.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of written prior to any study-related procedures;
  • Age ≥ 18 years;
  • Episode of AHF requiring hospital admission and treatment with intravenous furosemide;
  • (NYHA) functional class II-IV;
  • NT-proBNP >1000 pg/mL or BNP >250 pg/mL, measured within a period not exceeding 24 hours prior to inclusion;
  • Transthoracic echocardiogram performed within the previous 24 months. All categories will be included: reduced LVEF (\<40%), mildly reduced LVEF (41-49%), and preserved LVEF (≥50%). In patients with preserved LVEF (HFpEF), congruent structural and/or functional echocardiographic abnormalities are required (left ventricular hypertrophy defined as septal or posterior wall thickness ≥11 mm, E/e' >9, or left atrial volume >32 mL/m²);
  • Signs of fluid overload, with at least two of the following: jugular venous distension (at least up to the sternocleidomastoid level, \~10 cm), lower limb edema, ascites, or pleural effusion confirmed by chest radiography or lung ultrasound
  • Treatment with oral furosemide at a dose of at least 40 mg/day within the previous month.

Exclusion criteria

Exclusion Criteria:

  • Symptomatic hyponatremia or plasma sodium level ≤125 mmol/L;
  • \<9 g/dL;
  • Hypokalemia: serum potassium \<3 mEq/L;
  • Chronic kidney disease with estimated (eGFR) \<15 mL/min/1.73 m²;
  • Hemodynamic instability at admission, defined as symptomatic hypotension;
  • Acute coronary syndrome, cardiogenic shock, or admission to the intensive care unit (ICU);
  • Severe infection (e.g., pneumonia, sepsis, leukocyte count ≥12,000/μL, C-reactive protein >50 mg/L, or positive COVID-19 test);
  • Requirement for inotropic agents;
  • \<3 months or, in the investigator's judgment, inability to comply with study procedures.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
223 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. Residual Congestion at 72 Hours

    Residual Congestion 72 hours after admission, defined as the presence of any of the following criteria: i) Congestion Clinical Score (CCS) ≥ 2; ii) Portal venous flow pulsatility \> 30%; iii) Estimated plasma volume status (ePVS) \> 5.5 mL/g.

    Time frame: 72 hours after admission.

Secondary outcomes

  1. Worsening Heart Failure at 30 days

    Worsening Heart Failure 30 days after hospital discharge, defined as any of the following: i) Hospital readmission for heart failure; ii) Emergency department visits for heart failure; iii) Visits to the heart failure unit requiring intravenous diuretic administration.

    Time frame: From hospital discharge to 30 days thereafter.

  2. Worsening Heart Failure at 3 months

    Worsening Heart Failure 3 months after hospital discharge, defined as any of the following: i) Hospital readmission for heart failure; ii) Emergency department visits for heart failure; iii) Visits to the heart failure unit requiring intravenous diuretic administration.

    Time frame: From hospital discharge to 3 months thereafter.

  3. 30-day all-cause mortality

    All-cause mortality 30 days after hospital discharge.

    Time frame: From hospital discharge to 30 days thereafter.

  4. 3-month all-cause mortality

    All-cause mortality 3 months after hospital discharge.

    Time frame: From hospital discharge to 3 months thereafter.

  5. 30-day combined event (all-cause mortality or worsening heart failure)

    All-cause mortality or worsening heart failure 30 days after hospital discharge.

    Time frame: From hospital discharge to 30 days thereafter.

  6. 3-month combined event (all-cause mortality or worsening heart failure)

    All-cause mortality or worsening heart failure 3 months after hospital discharge.

    Time frame: From hospital discharge to 3 months thereafter.

07

Study locations

1 of 4 sites recruiting
08

References and documents

Publications

  • Campos J, Llacer P, Croset F, Garcia M, Perez C, Perez A, Vergara M, Cevallos P, Fabregate M, Fernandez C, Ruiz R, Useros D, Menacho M, Dominguez M, Perez E, Nunez J, Manzano L. Dynamics of urinary chloride and sodium and their link to decongestion in acute heart failure and preserved ejection fraction: NACLOCRo-HF study. ESC Heart Fail. 2025 Dec;12(6):4336-4348. doi: 10.1002/ehf2.15436. Epub 2025 Oct 13. PubMed 41078081 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Dec 2028, 31 months after the start.

Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 31 months is below that.

Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2026
First posted
May 19, 2026
StartActual
May 6, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 28, 2026
Sites
4 sites changed recruiting status (3 now not yet recruiting, 1 now recruiting)
Show 4 sites
  • Hospital de Olot i Comarcal de la Garrotxa · Olot, Spainno status→Not yet recruiting
  • Hospital Universitario Ramon y Cajal · Madrid, Spainno status→Recruiting
  • Hospital Universitario Puerta de Hierro Majadahonda · Majadahonda, Spainno status→Not yet recruiting
  • Hospital Clínico Universitario de Valencia · Valencia, Spainno status→Not yet recruiting
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Not yet recruiting→Recruiting
    4 sites changed recruiting status (3 now not yet recruiting, 1 now recruiting)
    Show 4 sites
    • Hospital de Olot i Comarcal de la Garrotxa · Olot, Spainno status→Not yet recruiting
    • Hospital Universitario Ramon y Cajal · Madrid, Spainno status→Recruiting
    • Hospital Universitario Puerta de Hierro Majadahonda · Majadahonda, Spainno status→Not yet recruiting
    • Hospital Clínico Universitario de Valencia · Valencia, Spainno status→Not yet recruiting
    + 3 other changes: verification date, date precision and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07597512
Lead sponsor
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Collaborators
Carlos III Health Institute
Responsible party
Sponsor
First posted
May 19, 2026
Start date
May 6, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Sep 28, 2026

Study contacts

Pau Llàcer Iborra, MD PhD
Contact
paullacer@hotmail.com
0034 913368000
Cristina Fernández Soler
Contact
cfsoler@salud.madrid.org
Pau Llàcer Iborra, MD PhD
principal investigator · Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal (FIBioHRC)
Luis Manzano Espinosa, MDPhD
principal investigator · Hospital Universitario Ramon y Cajal

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion